© The Author 2006. Published by Oxford University Press.
CORRESPONDENCE |
Central Nervous System Toxicity Induced by Irinotecan
Affiliations of authors: Departments of Internal Medicine (PH, DBH) and Neurology (RCJMD), Diakonessenhuis Utrecht, Utrecht, The Netherlands
Correspondence to: Paul Hamberg, MD, Erasmus MCDaniel den Hoed Cancer Center, Department of Medical Oncology, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands (e-mail: paulhamberg@yahoo.com).
| The first 10% of the full text of this article appears below. |
Irinotecan is a semisynthetic derivative of camptothecin that requires bioactivation to form the active metabolite 7-ethyl-10-hydroxycampthothecin (SN-38). The antitumor activity SN-38 is mediated through its inhibition of topoisomerase I. Irinotecan is used mainly to treat patients with disseminated colorectal carcinoma (1).
A 46-year-old man who was diagnosed with a sigmoid carcinoma and liver metastasis